ARAY Stock Forecast 2025-2026
Distance to ARAY Price Targets
ARAY Price Momentum
🤔 Considering Accuray (ARAY)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Latest ARAY Stock Price Targets & Analyst Predictions
Based on our analysis of 6 Wall Street analysts, ARAY has a bullish consensus with a median price target of $6.00 (ranging from $5.50 to $7.00). Currently trading at $1.83, the median forecast implies a 227.9% upside. This outlook is supported by 4 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Marie Thibault at BTIG, projecting a 282.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ARAY Analyst Ratings
ARAY Price Target Range
Latest ARAY Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ARAY.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 13, 2024 | Roth MKM | Jason Wittes | Buy | Initiates | $9.00 |
| Oct 4, 2023 | B. Riley Securities | Neil Chatterji | Buy | Reiterates | $7.50 |
| Aug 31, 2022 | B. Riley Securities | Buy | Initiates | $0.00 | |
| Jun 24, 2022 | BTIG | Marie Thibault | Buy | Maintains | $7.00 |
| Jun 23, 2022 | B. Riley Securities | Kara Anderson | Buy | Initiates | $7.50 |
| Dec 22, 2021 | Loop Capital | Buy | Initiates | $0.00 | |
| Jan 21, 2020 | BTIG | Buy | Upgrade | $0.00 | |
| Jan 21, 2020 | BTIG Research | Buy | Upgrade | $0.00 | |
| Nov 1, 2018 | Citigroup | Amit Hazan | Neutral | Upgrade | $3.90 |
| Aug 17, 2018 | Citigroup | Sell | Maintains | $3.50 | |
| Dec 19, 2017 | JP Morgan | Underweight | Downgrade | $0.00 | |
| Dec 13, 2017 | JP Morgan | Underweight | Downgrade | $0.00 | |
| Nov 30, 2017 | Lake Street | Buy | Initiates | $0.00 | |
| Aug 23, 2017 | Jefferies | Buy | Maintains | $6.00 | |
| Feb 6, 2017 | Aegis Capital | Buy | Initiates | $0.00 | |
| Dec 14, 2016 | JP Morgan | Neutral | Downgrade | $0.00 | |
| Sep 13, 2016 | Cowen & Co. | Outperform | Initiates | $0.00 | |
| Dec 22, 2015 | RBC Capital | Sector Perform | Initiates | $0.00 | |
| Nov 12, 2015 | Citigroup | Sell | Initiates | $0.00 | |
| Jan 12, 2015 | Northland Capital Markets | Outperform | Initiates | $0.00 |
Accuray Incorporated (ARAY) Competitors
The following stocks are similar to Accuray based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Accuray Incorporated (ARAY) Financial Data
Accuray Incorporated has a market capitalization of $189.21M with a P/E ratio of -11.4x. The company generates $453.14M in trailing twelve-month revenue with a -1.0% profit margin.
Revenue growth is +16.8% quarter-over-quarter, while maintaining an operating margin of +3.7% and return on equity of -9.2%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Accuray Incorporated (ARAY) Business Model
About Accuray Incorporated
Develops precise tumor treatment medical devices.
Accuray Incorporated generates revenue by designing, manufacturing, and selling advanced radiation therapy systems, such as the CyberKnife and TomoTherapy systems. These devices are utilized in various healthcare facilities worldwide, allowing the company to capitalize on the growing demand for effective cancer treatment solutions.
The company is focused on improving cancer care through innovative technology and patient-centered approaches, aiming to enhance treatment outcomes and the quality of life for patients. Accuray holds a significant position in the oncology sector, contributing to advancements in radiation therapy techniques.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
987
CEO
Ms. Suzanne Winter M.B.A.
Country
United States
IPO Year
2007
Website
www.accuray.comAccuray Incorporated (ARAY) Latest News & Analysis
Accuray Incorporated (NASDAQ: ARAY) will participate in the 37th Annual Roth Conference from March 16-18, 2025, in Dana Point, California.
Accuray's participation in the Roth Conference could signal potential investor interest, provide visibility, and lead to new partnerships or funding opportunities, impacting its stock performance.
ARAY reports strong performance in its CyberKnife system and overall global operations, indicating positive growth prospects.
ARAY's strong performance in its CyberKnife system indicates sustained demand and potential revenue growth, positively impacting investor confidence and stock valuation.
Accuray reported strong fiscal Q2 results, with increased product revenues and decreased operating expenses, indicating positive financial performance.
Accuray's strong fiscal Q2 results indicate improving financial health, which can lead to increased investor confidence and potential stock price appreciation.
Accuray Inc. (NASDAQ: ARAY) will hold its Q2 2025 financial results conference call on February 5, 2025, at 4:30 PM ET, featuring key executives and analysts.
Accuray's Q2 earnings call signals potential insights into financial performance and strategic direction, impacting stock valuation and investor sentiment.
Accuray Incorporated (NASDAQ: ARAY) released its financial results for Q2 ending December 31, 2024, on February 5, 2025.
Accuray's financial results can impact stock performance, influencing investor sentiment, valuation, and future growth expectations for the company.
Accuray's Q4 2024 revenue and EPS are available, but comparison with Wall Street estimates and prior year metrics is advised for a complete assessment.
Accuray's revenue and EPS performance relative to Wall Street estimates and year-ago figures can indicate growth potential and market confidence, influencing stock valuation and investor sentiment.
Frequently Asked Questions About ARAY Stock
What is Accuray Incorporated's (ARAY) stock forecast for 2025?
Based on our analysis of 6 Wall Street analysts, Accuray Incorporated (ARAY) has a median price target of $6.00. The highest price target is $7.00 and the lowest is $5.50.
Is ARAY stock a good investment in 2025?
According to current analyst ratings, ARAY has 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.83. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ARAY stock?
Wall Street analysts predict ARAY stock could reach $6.00 in the next 12 months. This represents a 227.9% increase from the current price of $1.83. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Accuray Incorporated's business model?
Accuray Incorporated generates revenue by designing, manufacturing, and selling advanced radiation therapy systems, such as the CyberKnife and TomoTherapy systems. These devices are utilized in various healthcare facilities worldwide, allowing the company to capitalize on the growing demand for effective cancer treatment solutions.
What is the highest forecasted price for ARAY Accuray Incorporated?
The highest price target for ARAY is $7.00 from Marie Thibault at BTIG, which represents a 282.5% increase from the current price of $1.83.
What is the lowest forecasted price for ARAY Accuray Incorporated?
The lowest price target for ARAY is $5.50 from at , which represents a 200.5% increase from the current price of $1.83.
What is the overall ARAY consensus from analysts for Accuray Incorporated?
The overall analyst consensus for ARAY is bullish. Out of 6 Wall Street analysts, 4 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $6.00.
How accurate are ARAY stock price projections?
Stock price projections, including those for Accuray Incorporated, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
